Conference Day Two

Thursday, 27th February

7:50 am Check-In & Morning Coffee

8:50 am Chair’s Opening Remarks

Exploring Investment Trends & Understanding the Investment Landscape to Manage Expectations & Make Cell Therapy More

9:00 am Learning from Successful IPOs & Investments to Understand the Best Way Forward to Increase Investments in Your Company

Synopsis

• Clarifying the reason behind the success of IPOs to ensure success for yourself

• Examining how to increase investments in your company to boost manufacturing and development

• Leveraging learnings to apply what worked and ensure high investments

9:30 am Panel Discussion: Mergers, Acquisitions, Investments: Everything You Need to Know About What the Investors Are Looking For

Synopsis

• Understanding the perspective of investors to understand what they are looking for

• Analysing pharma’s needs to understand how to partner with them

• Having an open dialogue with investors to clarify what you are looking for and how they can help

10.15 Morning Networking Break

Track A: Discovery
Track A: Discovery

Outlining Approaches to Solid Tumours to Improve Efficacy & Durability in Tumour Microenvironment

11:45am: Enhancing TCR-T Cell Potency in Solid Tumours with Next-Generation Toolbox Technologies

• Enabling TCR-T cells to overcome the suppressive tumour
microenvironment

• Augmenting T-cell performance and efficacy

• Reducing exhaustion to improve therapeutic durability

Felix Lorenz, Chief Executive Officer/ Chief Scientific Officer, Captain T Cell

12:15pm: Group Discussion: Validating Novel Targets to Understand the Impact of Cell Therapy on Them & Maximise Safety

• Understanding tumour and target mechanism

• Analysing how to convince the regulators that the novel target
makes sense

• Reviewing the novel target to ensure you are not instigating a
safety signal

12:45pm: Unlocking the Solid Tumour Landscape Through High-Sensitivity CAR-T

• Problem of current (low-sensitivity) CAR constructs

• MatchBio’s proprietary platform for generating of novel high
sensitivity CAR-T

• Application of MatchBio technology to unlock novel CAR-T
targets in solid tumour

Omer Dushek, Founder, MatchBio

1:15pm: Afternoon Break & Poster Session

Outlining Approaches to Solid Tumours to Improve Efficacy & Durability in Tumour Microenvironment

2:15pm: Redesigning CAR Structure to Bridge the Gap & Access Solid Tumours to Improve Efficacy of CAR-T Therapy

• Changing the intrinsic CAR structure to identify solid tumour targets

• Reimagining CAR engineering to make it more sensitive to solid tumour targets

• Translating existing CARs with success in blood tumours to solid tumours

Laurent Poirot, Senior Vice President, Immunology, Cellectis

2:45pm: Exploring Advancements in CAR-T for Solid Tumours

• Overcoming the challenges of the tumour microenvironment

• Utilising the antigen presenting cell functions of gamma delta
cells to elicit a secondary response

• An allogeneic approach

Jeff Liter, Founder & Chief Executive Officer, Luminary Therapeutics

3:45pm: Session reserved for Hooke Bio

4:00pm: Chimeric ILT-Receptor (CIR™) Allogeneic Technology Effectively Targets HLA-G+ Hematologic & Solid Tumours for Fit-for-Purpose Activation of NK Cells

• CIR™NK cells efficacy and safety in HLAG+ AML, hematologic and solid tumours (animal models data)

• Allogeneic technology to improve patient access and contain manufacturing costs

• Overview of the path to 2 IND with expected FIH clinical trial to start in 2027

Raphaël Ognar, President & Chief Executive Officer, NKILT
Therapeutics

Track B: Clinical Development
Track C: CMC, Process & Analytics/ Clinical

3:55 pm Afternoon Networking Break

Exploring the CAR-TCR Landscape & Understanding the Progress in the Field to Propel Clinical Development

4:30 pm A Landscape Overview of CAR & TCR Therapies

Synopsis

• Reviewing current trends in the CAR and TCR therapy landscape

• Which platform technologies and innovations are developers utilising in an increasingly competitive space?

• Harnessing the insights of Beacon to accelerate the clinical development of your own cell therapy pipeline

5:00 pm Session Reserved for New Clinical Data

5:30 pm Chair’s Closing Remarks

5:35 pm End of Conference

DAY ONE
REGISTER
PARTNER